Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel

Access this Article

Search this Article

Author(s)

    • Matsubara Yuki
    • Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan
    • Fujinami Haruka
    • Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan
    • Sugiyama Toshiro
    • Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan
    • Ando Takayuki
    • Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan
    • Hosokawa Ayumu
    • Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan
    • Mihara Hiroshi
    • Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan
    • Takagi Hiroaki
    • Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan
    • Nakata Naokatsu
    • Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan
    • Yoshita Hiroki
    • Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan
    • Nanjo Sohachi
    • Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan
    • Kajiura Shinya
    • Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Japan

Abstract

<p>Extrapulmonary neuroendocrine carcinoma (NEC) is a rare disease, and there is no standard chemotherapy. A 73-year-old man was diagnosed with advanced gastric NEC. He received chemotherapy of irinotecan plus cisplatin, and amrubicin monotherapy. After failure of second-line chemotherapy, he received ramucirumab plus paclitaxel; this treatment was chosen because vascular endothelial growth factor 2 was strongly expressed in the tumor endothelial cells. After two cycles, his NEC had markedly reduced in size, and he continued with this treatment for over eight months. In this case, the combination of an anti-angiogenic inhibitor and a cytotoxic agent was highly effective for gastric NEC. </p>

Journal

  • Internal Medicine

    Internal Medicine 57(5), 671-675, 2018

    The Japanese Society of Internal Medicine

Codes

Page Top